Which finding best distinguishes the oxidative phase of the pentose phosphate pathway from the non-oxidative phase in terms of metabolic outcome and cellular function?

Explanation

## Oxidative vs. Non-Oxidative Phases of the Pentose Phosphate Pathway ### Fundamental Distinction **Key Point:** The oxidative phase generates NADPH (reducing power for biosynthesis and antioxidant defense), while the non-oxidative phase rearranges sugar phosphates to produce ribose-5-phosphate (for nucleotide synthesis) and regenerate glucose-6-phosphate (for glycolysis). Neither phase generates ATP. ### Phase Comparison Table | Feature | Oxidative Phase | Non-Oxidative Phase | | --- | --- | --- | | **Substrate** | Glucose-6-phosphate | Ribulose-5-phosphate (or pentose phosphates) | | **Product** | NADPH + CO~2~ + Ribulose-5-P | Glucose-6-phosphate + Glyceraldehyde-3-P | | **Primary function** | Reducing power (biosynthesis, antioxidant) | Sugar rearrangement (nucleotides, glycolysis) | | **Reversibility** | Irreversible (oxidative step) | Reversible (transketolase, transaldolase) | | **Enzyme types** | Oxidoreductases (G6PD, 6PGDH) | Transferases (transketolase, transaldolase) | | **Regulation** | Feedback inhibited by NADPH | Depends on substrate availability | | **ATP generated** | No | No | | **Location** | Cytoplasm | Cytoplasm | ### High-Yield: The Two Metabolic Roles **High-Yield:** The pentose phosphate pathway serves two distinct metabolic roles: 1. **Oxidative phase** → NADPH for reductive biosynthesis (fatty acids, cholesterol, nucleotides) and antioxidant defense (GSH reduction). 2. **Non-oxidative phase** → Ribose-5-phosphate for nucleotide synthesis and flexible sugar rearrangement to feed glycolysis. ### Reaction Sequences ```mermaid flowchart TD A[Glucose-6-phosphate]:::outcome --> B[G6PD enzyme]:::action B --> C[6-Phosphogluconate]:::outcome C --> D[6PGDH enzyme]:::action D --> E[Ribulose-5-phosphate + 2 NADPH]:::outcome E --> F{Metabolic need?}:::decision F -->|Nucleotides| G[Ribose-5-phosphate]:::action F -->|Glycolysis| H[Non-oxidative rearrangement]:::action H --> I[Glucose-6-phosphate + Glyceraldehyde-3-P]:::outcome J[NADPH]:::outcome --> K[Fatty acid synthesis]:::action J --> L[Cholesterol synthesis]:::action J --> M[Glutathione reduction]:::action ``` ### Clinical Pearl **Clinical Pearl:** Tissues with high biosynthetic demand (liver, adipose, mammary gland, adrenal cortex) and tissues under oxidative stress (RBCs, lens, cornea) have the highest pentose phosphate pathway activity. G6PD deficiency is most symptomatic in RBCs because they rely entirely on this pathway for antioxidant defense. **Mnemonic: OX = Oxidative phase makes NADPH (reducing power); NON-OX = Non-Oxidative phase makes sugars and regenerates glucose.** [cite:Lehninger Principles of Biochemistry 7e Ch 20]